We also provided strong evidence from the current stage of literature about clinical trials of targeting HER2-altered CCA using several strategies of immunotherapy that provide favorable clinical outcomes and emerging HER2 as the potential target for CCA immunotherapy shortly. The gene discussed is ERBB2; the disease is cholangiocarcinoma.